# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and t...
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, w...
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and c...
OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030.NE...